医疗设备制造商德康医疗(DXCM)盘前大跌7.83%,引发市场广泛关注。尽管公司第三季度营收和利润均超出分析师预期,但重申了较为保守的2024年全年销售预期,这引发了投资者对公司未来增长前景的担忧。
德康医疗第三季度实现营收3.45亿美元,同比增长29%,主要得益于其连续性血糖监测设备在糖尿病患者中的强劲需求。但公司同时重申了2024年全年销售额预期约为40亿至40.5亿美元。
多位分析师指出,这一全年预期略显保守,暗示公司增长可能放缓。部分投资者担心,如果公司在销售团队重组、客户流失等问题未完全解决,增长动力或将继续减弱。Leerink Partners分析师Mike Kratky表示:"在公司似乎制定了相对保守的指导之后,维持展望可能会让一些投资者感到失望。"
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.